lung cancer

[GenFleet Therapeutics] GenFleet Therapeutics announced the first patient with metastatic sigmoid adenocarcinoma has been dosed in a Phase Ib/II trial of GFH018 in combination with toripalimab as part of global multi-center clinical research. There are broad indications for GFH018 in treating solid tumors with lower response rates to PD-1 inhibitors.

[Scientific Reports] Scientists investigated the possibility that periostin secreted by fibroblasts derived from idiopathic pulmonary fibrosis lung might have affected proliferation of non-small cell lung cancer cells.

[Human Cell] Researchers elucidated the role of histone deacetylase 6 in regulating epithelial-mesenchymal transition-mediated metastasis via mRNA in NSCLC.

[Acta Histochemica] Researchers identified the morphological characteristics of the neuroendocrine phenotype in a human lung cancer cell line, induced by two cAMP elevating agents.

[European Respiratory Review] The authors review the relevant literature in this rapidly expanding field, including results from mouse models and human studies. In addition, they present a case for club cells as cells of origin of lung adenocarcinomas that arise in smokers.

[Ultimovacs ASA] Ultimovacs ASA announced that the company’s universal cancer vaccine, UV1, will be investigated in a new Phase II clinical trial in combination with pembrolizumab in NSCLC.